Immunotherapy of multiple sclerosis.
Multiple sclerosis (MS) is regarded as a prototypic inflammatory autoimmune central nervous system disorder causing neurological disability in young adults. Recommended basic immunomodulatory therapies of MS are currently interferon beta and glatiramer acetate. Both have proven to be clinically and paraclinically effective and clinical evidence suggests that treatment should be initiated as early as possible. However, despite the fact that therapeutic options for MS have significantly been widened over the past decade there is still tremendous activity in the search for new treatment options for MS. One important development in the field is reflected by the substantial number of promising results for oral therapies. Various phase III clinical trials are currently being initiated or are already underway evaluating the efficacy of a variety of orally administered agents, including cladribine, teriflunomide, laquinimod, fingolimod and fumaric acid. It is hoped that these oral therapies for MS further broaden our armament for MS therapy.
Department of Neurology, University of Würzburg, Würzburg, Germany.
Sven G
SG
Meuth
Department of Neurology, University of Würzburg, Würzburg, Germany.
Stefan
S
Bittner
Department of Neurology, University of Würzburg, Würzburg, Germany.
Heinz
H
Wiendl